What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to officially announce Abbott Laboratories' financial results for the third quarter of 2019 and to furnish the accompanying press release which details these results.

What are non-GAAP financial measures, and why does Abbott use them?

Non-GAAP financial measures are financial metrics that exclude certain items from GAAP-based results. Abbott uses them to provide investors with a clearer perspective on the company's ongoing operational performance by excluding costs that are unusual, unpredictable, or not reflective of core business activities, such as acquisition expenses, restructuring costs, and debt extinguishment charges.

How should investors interpret Abbott's use of non-GAAP measures?

Investors should view Abbott's non-GAAP financial measures as supplementary information. While they can offer insights into underlying business performance, they should always be considered in conjunction with, and not as a replacement for, the company's financial results prepared in accordance with Generally Accepted Accounting Principles (GAAP).

Where can I find the detailed Q3 2019 results?

The detailed third-quarter 2019 results are provided in the press release furnished as Exhibit 99.1 to this 8-K filing.

ABT 8-K: Earnings & Results

Summary

Abbott Laboratories (ABT) filed an 8-K on October 16, 2019, to announce its third-quarter 2019 financial results. The report primarily furnished a press release detailing these results, which included the company's use of non-GAAP financial measures. These adjusted measures, excluding items like acquisition and restructuring costs, R&D asset acquisition impacts, debt extinguishment costs, and impairment charges, are presented by Abbott to offer investors a clearer view of ongoing business performance, as management uses them internally for assessment. Investors should note that while Abbott believes these non-GAAP measures provide valuable insight, they are intended to supplement, not replace, Generally Accepted Accounting Principles (GAAP) financial measures. The filing also lists the press release as an exhibit. This 8-K serves as the official notification of the company's Q3 2019 performance announcement.

Key Highlights

1Abbott Laboratories announced its third-quarter 2019 results via an 8-K filing on October 16, 2019.
2The filing incorporates a press release (Exhibit 99.1) containing the detailed Q3 2019 financial results.
3Abbott utilizes non-GAAP financial measures in its results announcement, excluding specified items.
4Examples of excluded items in non-GAAP measures include acquisition/restructuring expenses, R&D asset costs, debt extinguishment, and impairment charges.
5The company states these non-GAAP measures are used to provide investors with greater visibility into ongoing business performance.
6Abbott's management also uses these non-GAAP measures for internal performance monitoring.
7Investors are cautioned to consider these non-GAAP measures alongside, and not as a substitute for, GAAP-based financial results.

ABBOTT LABORATORIES 8-K Report, Financial Results (Oct 16, 2019)

Summary

Key Highlights

Frequently Asked Questions